论文部分内容阅读
目的观察还原型谷胱甘肽对帕金森病人临床疗效及安全性。方法选择77例帕金森病病人,随机分为对照组38例、治疗组39例,两组均常规抗PD治疗,而治疗组联用谷胱甘肽,连续4周,治疗前后行血SOD、GSH-Px、MDA测定;治疗组、对照组进行治疗前后H-Y分级及帕金森病统一评分量表的第二分量表(UPDRSII)评定临床疗效。结果GSH治疗后,SOD、GSH-Px值较治疗前明显升高(P<0.05、P<0.01),MDA值下降(P<0.05),而对照组改变不明显。治疗前后UPDRSII评分及H-Y分级有明显改善(P<0.05、P<0.01),与对照组比较,疗后UPDRSII评分两组有显著差异(P<0.05)。结论在短期临床观察中GSH对PD病人有较显著的治疗作用。
Objective To observe the clinical efficacy and safety of reduced glutathione in Parkinson’s disease. Methods A total of 77 patients with Parkinson’s disease were randomly divided into control group (n = 38) and treatment group (n = 39). Both groups were given anti-PD treatment routinely. The treatment group was treated with glutathione for 4 weeks, GSH-Px, MDA were measured. The therapeutic effect was evaluated by the HY scale and the Parkinson’s Disease Uniform Rating Scale (UPDRSII) before and after treatment in the treatment group and the control group. Results After treatment with GSH, the levels of SOD and GSH-Px were significantly higher than those before treatment (P <0.05, P <0.01), while the MDA values were decreased (P <0.05), but not in the control group. UPDRSII score and H-Y grade were significantly improved before and after treatment (P <0.05, P <0.01). Compared with control group, UPDRSII score after treatment showed significant difference (P <0.05). Conclusion GSH has a significant therapeutic effect on PD patients in short-term clinical observation.